Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
Why Intra-Cellular Therapies Is Surging Today
Why Intra-Cellular Therapies Is Surging Today
Shares of Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage pharma company focused on diseases of the central nervous system, jumped more than 17% as of 3:15 p.m. EDT on Thursday. The....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
Why Clovis Oncology Fell 7.1% in August
Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed....

	 
BOIRON : Résultats semestriels 2017
BOIRON : Résultats semestriels 2017
(Données ayant fait l'objet d'une revue limitée par les commissaires aux comptes) Le Conseil d'Administration de BOIRON, réuni le 7 septembre 2017, a établi les comptes sociaux et les comptes....

	 
BOIRON : 2017 half-year results
BOIRON : 2017 half-year results
(Data have been the subject to a limited review by the statutory auditors) The Board of Directors of BOIRON, at its meeting of September 7, 2017, made up the half-year statutory and....
Here's Why Shire PLC Stock Fell 10% in August
Here's Why Shire PLC Stock Fell 10% in August
Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence.....
Why Fitbit Stock Is Soaring Today
Why Fitbit Stock Is Soaring Today
Shares of fitness wearables company Fitbit (NYSE: FIT) surged on Thursday following the announcement of a partnership with medical-device maker DexCom (NASDAQ: DXCM) related to glucose monitoring.....
Why Fitbit Stock Is Soaring Today
Why Fitbit Stock Is Soaring Today
Shares of fitness wearables company Fitbit (NYSE: FIT) surged on Thursday following the announcement of a partnership with medical-device maker DexCom (NASDAQ: DXCM) related to glucose monitoring.....
Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today
Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) a clinical-stage biotech developing RNA-based therapies to treat rare diseases, announced an immediate halt to all studies with one of the....
Why Illumina Rose 18.7% in August
Why Illumina Rose 18.7% in August
Shares of Illumina (NASDAQ: ILMN), a leading manufacturer of genetic testing equipment, rose 18.7% in August, according to data from S&P Global Market Intelligence. Investors can thank solid....
Why Illumina Rose 18.7% in August
Why Illumina Rose 18.7% in August
Shares of Illumina (NASDAQ: ILMN), a leading manufacturer of genetic testing equipment, rose 18.7% in August, according to data from S&P Global Market Intelligence. Investors can thank solid....
Why Illumina Rose 18.7% in August
Why Illumina Rose 18.7% in August
Shares of Illumina (NASDAQ: ILMN), a leading manufacturer of genetic testing equipment, rose 18.7% in August, according to data from S&P Global Market Intelligence. Investors can thank solid....
Here's Why Cara Therapeutics Rose 9.6% in August
Here's Why Cara Therapeutics Rose 9.6% in August
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech focused on drugs that relieve pain, rose by nearly 10% during August, according to data from S&P Global Market Intelligence. The jump....
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
It's been a busy week for biotech and healthcare conferences. Drugmakers big and small have been making the rounds, answering questions about their current status and future prospects. Celgene....
5 Key Things You Should Watch With Jazz Pharmaceuticals
5 Key Things You Should Watch With Jazz Pharmaceuticals
It's been a great year for Jazz Pharmaceuticals (NASDAQ: JAZZ) shareholders so far. The biotech stock is up more than 35% year to date. However, most of those gains were made in the first....
Evotec: Gute News zum Handelsstart
Evotec: Gute News zum Handelsstart
Der Wirkstoffhersteller Evotec meldet heute vorbörslich den Abschluss einer neuen Forschungs-Kooperation. Zusammen mit ABIVAX soll am französischen Standort im Bereich „Behandlung von schweren....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....